' 
![]()
SCIENTIFIC SCORE
Likely Very Effective
Based on 2 Researches
9
USERS' SCORE
Good
Based on 1 Review
8.6
Supplement Facts
Serving Size: 2 Tablets
Amount Per Serving
%DV
MSM (Methylsulfonylmethane)
3 g (3,000 mg)
*
Top Medical Research Studies
9
MSM improves migraine management
Acute migraine medication adherence, migraine disability and patient satisfaction: A naturalistic daily diary study.
Strong relevance to migraine treatment
We aimed to understand how adherence to migraine-specific medications (MSMs) influences migraine-related disability and patient satisfaction. Over three months, 337 participants used daily electronic diaries to track their migraine experiences, including the medications they took and their satisfaction with these treatments.
It was insightful to see that participants took their acute medications on a staggering 96.5% of the days they recorded migraines. Among the medications used, MSMs were the most common at 58%, followed by over-the-counter analgesics and opiates/barbiturates. We found that people tended to reach for medication when their pain was mild most often.
Our analysis showed that when individuals used MSMs during mild pain, they experienced the least daily disability and reported the highest satisfaction with their medications. This implies that using MSMs earlier, especially at the onset of milder symptoms, can significantly improve a patient's overall experience with migraines.
In conclusion, our study highlights the benefits of starting treatment with MSMs for better outcomes in managing migraine-related challenges and achieving greater satisfaction with acute medication usage.
It was insightful to see that participants took their acute medications on a staggering 96.5% of the days they recorded migraines. Among the medications used, MSMs were the most common at 58%, followed by over-the-counter analgesics and opiates/barbiturates. We found that people tended to reach for medication when their pain was mild most often.
Our analysis showed that when individuals used MSMs during mild pain, they experienced the least daily disability and reported the highest satisfaction with their medications. This implies that using MSMs earlier, especially at the onset of milder symptoms, can significantly improve a patient's overall experience with migraines.
In conclusion, our study highlights the benefits of starting treatment with MSMs for better outcomes in managing migraine-related challenges and achieving greater satisfaction with acute medication usage.
Read More
9
Erenumab reduces migraine medication use
Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials.
Moderate relevance to MSM effects
We explored how treatment with erenumab affects the use of acute migraine medications. This study analyzed data from two large clinical trials involving nearly 1,600 participants suffering from episodic migraine (EM) and chronic migraine (CM). Patients received either erenumab or a placebo monthly for treatment, while they recorded their medication usage in an electronic diary.
Our findings highlighted that erenumab not only reduces the frequency of acute headaches but also leads to a significant decrease in the use of acute headache medications, particularly migraine-specific medications like triptans and ergots. This suggests that treating migraines with erenumab may help minimize the risk of over-reliance on acute medication, which can sometimes lead to adverse health situations, such as medication overuse headache.
Overall, the treatment with erenumab proves promising for anyone looking to manage their migraine efficiently, allowing patients to experience relief while reducing their dependency on other acute medications.
Our findings highlighted that erenumab not only reduces the frequency of acute headaches but also leads to a significant decrease in the use of acute headache medications, particularly migraine-specific medications like triptans and ergots. This suggests that treating migraines with erenumab may help minimize the risk of over-reliance on acute medication, which can sometimes lead to adverse health situations, such as medication overuse headache.
Overall, the treatment with erenumab proves promising for anyone looking to manage their migraine efficiently, allowing patients to experience relief while reducing their dependency on other acute medications.
Read More
Most Useful Reviews
9.5
Life-changing product
This product has truly changed my life. I used to suffer from allergy-triggered migraines, but halfway through using it, they ceased along with other allergy symptoms. It also alleviated my back and joint pain significantly. I wish I had learned about MSM from my doctors sooner.
Read More
Medical Researches
SCIENTIFIC SCORE
Likely Very Effective
Based on 2 Researches
9
9
Erenumab reduces migraine medication use
Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials.
Moderate relevance to MSM effects
We explored how treatment with erenumab affects the use of acute migraine medications. This study analyzed data from two large clinical trials involving nearly 1,600 participants suffering from episodic migraine (EM) and chronic migraine (CM). Patients received either erenumab or a placebo monthly for treatment, while they recorded their medication usage in an electronic diary.
Our findings highlighted that erenumab not only reduces the frequency of acute headaches but also leads to a significant decrease in the use of acute headache medications, particularly migraine-specific medications like triptans and ergots. This suggests that treating migraines with erenumab may help minimize the risk of over-reliance on acute medication, which can sometimes lead to adverse health situations, such as medication overuse headache.
Overall, the treatment with erenumab proves promising for anyone looking to manage their migraine efficiently, allowing patients to experience relief while reducing their dependency on other acute medications.
Our findings highlighted that erenumab not only reduces the frequency of acute headaches but also leads to a significant decrease in the use of acute headache medications, particularly migraine-specific medications like triptans and ergots. This suggests that treating migraines with erenumab may help minimize the risk of over-reliance on acute medication, which can sometimes lead to adverse health situations, such as medication overuse headache.
Overall, the treatment with erenumab proves promising for anyone looking to manage their migraine efficiently, allowing patients to experience relief while reducing their dependency on other acute medications.
Read More
9
MSM improves migraine management
Acute migraine medication adherence, migraine disability and patient satisfaction: A naturalistic daily diary study.
Strong relevance to migraine treatment
We aimed to understand how adherence to migraine-specific medications (MSMs) influences migraine-related disability and patient satisfaction. Over three months, 337 participants used daily electronic diaries to track their migraine experiences, including the medications they took and their satisfaction with these treatments.
It was insightful to see that participants took their acute medications on a staggering 96.5% of the days they recorded migraines. Among the medications used, MSMs were the most common at 58%, followed by over-the-counter analgesics and opiates/barbiturates. We found that people tended to reach for medication when their pain was mild most often.
Our analysis showed that when individuals used MSMs during mild pain, they experienced the least daily disability and reported the highest satisfaction with their medications. This implies that using MSMs earlier, especially at the onset of milder symptoms, can significantly improve a patient's overall experience with migraines.
In conclusion, our study highlights the benefits of starting treatment with MSMs for better outcomes in managing migraine-related challenges and achieving greater satisfaction with acute medication usage.
It was insightful to see that participants took their acute medications on a staggering 96.5% of the days they recorded migraines. Among the medications used, MSMs were the most common at 58%, followed by over-the-counter analgesics and opiates/barbiturates. We found that people tended to reach for medication when their pain was mild most often.
Our analysis showed that when individuals used MSMs during mild pain, they experienced the least daily disability and reported the highest satisfaction with their medications. This implies that using MSMs earlier, especially at the onset of milder symptoms, can significantly improve a patient's overall experience with migraines.
In conclusion, our study highlights the benefits of starting treatment with MSMs for better outcomes in managing migraine-related challenges and achieving greater satisfaction with acute medication usage.
Read More
User Reviews
USERS' SCORE
Good
Based on 1 Review
8.6
9.5
Life-changing product
This product has truly changed my life. I used to suffer from allergy-triggered migraines, but halfway through using it, they ceased along with other allergy symptoms. It also alleviated my back and joint pain significantly. I wish I had learned about MSM from my doctors sooner.
